vs
Side-by-side financial comparison of ASSURED GUARANTY LTD (AGO) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
ASSURED GUARANTY LTD is the larger business by last-quarter revenue ($277.0M vs $185.2M, roughly 1.5× AMICUS THERAPEUTICS, INC.). ASSURED GUARANTY LTD runs the higher net margin — 43.0% vs 0.9%, a 42.0% gap on every dollar of revenue. On growth, ASSURED GUARANTY LTD posted the faster year-over-year revenue change (77.6% vs 23.7%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 6.3%).
Assured Investment Management (AIM) was an institutional asset management firm with a heritage in credit strategies, managing approximately $15.2 billion as of its defunct status in July 2023. Secondaries Investors referred to AIM as "one of the world's most prominent hedge funds".
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
AGO vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $277.0M | $185.2M |
| Net Profit | $119.0M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | 59.6% | 8.6% |
| Net Margin | 43.0% | 0.9% |
| Revenue YoY | 77.6% | 23.7% |
| Net Profit YoY | 561.1% | -88.5% |
| EPS (diluted) | $2.56 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $277.0M | $185.2M | ||
| Q3 25 | $207.0M | $169.1M | ||
| Q2 25 | $281.0M | $154.7M | ||
| Q1 25 | $345.0M | $125.2M | ||
| Q4 24 | $156.0M | $149.7M | ||
| Q3 24 | $269.0M | $141.5M | ||
| Q2 24 | $202.0M | $126.7M | ||
| Q1 24 | $245.0M | $110.4M |
| Q4 25 | $119.0M | $1.7M | ||
| Q3 25 | $105.0M | $17.3M | ||
| Q2 25 | $103.0M | $-24.4M | ||
| Q1 25 | $176.0M | $-21.7M | ||
| Q4 24 | $18.0M | $14.7M | ||
| Q3 24 | $171.0M | $-6.7M | ||
| Q2 24 | $78.0M | $-15.7M | ||
| Q1 24 | $109.0M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | 59.6% | 8.6% | ||
| Q3 25 | 65.2% | 20.3% | ||
| Q2 25 | 47.3% | -6.1% | ||
| Q1 25 | 66.4% | -6.3% | ||
| Q4 24 | 19.2% | 10.7% | ||
| Q3 24 | 81.8% | 15.3% | ||
| Q2 24 | 46.5% | 11.8% | ||
| Q1 24 | 58.8% | -25.1% |
| Q4 25 | 43.0% | 0.9% | ||
| Q3 25 | 50.7% | 10.2% | ||
| Q2 25 | 36.7% | -15.8% | ||
| Q1 25 | 51.0% | -17.3% | ||
| Q4 24 | 11.5% | 9.8% | ||
| Q3 24 | 63.6% | -4.8% | ||
| Q2 24 | 38.6% | -12.4% | ||
| Q1 24 | 44.5% | -43.9% |
| Q4 25 | $2.56 | $0.00 | ||
| Q3 25 | $2.18 | $0.06 | ||
| Q2 25 | $2.08 | $-0.08 | ||
| Q1 25 | $3.44 | $-0.07 | ||
| Q4 24 | $0.40 | $0.05 | ||
| Q3 24 | $3.17 | $-0.02 | ||
| Q2 24 | $1.41 | $-0.05 | ||
| Q1 24 | $1.89 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $903.0M | $293.5M |
| Total DebtLower is stronger | $1.7B | $392.7M |
| Stockholders' EquityBook value | $5.7B | $274.2M |
| Total Assets | $12.2B | $949.9M |
| Debt / EquityLower = less leverage | 0.30× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $903.0M | $293.5M | ||
| Q3 25 | $1.3B | $263.8M | ||
| Q2 25 | $939.0M | $231.0M | ||
| Q1 25 | $1.2B | $250.6M | ||
| Q4 24 | $1.2B | $249.9M | ||
| Q3 24 | $1.5B | $249.8M | ||
| Q2 24 | $1.7B | $260.1M | ||
| Q1 24 | $1.6B | $239.6M |
| Q4 25 | $1.7B | $392.7M | ||
| Q3 25 | $1.7B | $392.0M | ||
| Q2 25 | $1.7B | $391.3M | ||
| Q1 25 | $1.7B | $390.7M | ||
| Q4 24 | $1.7B | $390.1M | ||
| Q3 24 | $1.7B | $389.5M | ||
| Q2 24 | $1.7B | $388.9M | ||
| Q1 24 | $1.7B | $388.4M |
| Q4 25 | $5.7B | $274.2M | ||
| Q3 25 | $5.7B | $230.4M | ||
| Q2 25 | $5.6B | $204.3M | ||
| Q1 25 | $5.6B | $193.6M | ||
| Q4 24 | $5.5B | $194.0M | ||
| Q3 24 | $5.7B | $178.8M | ||
| Q2 24 | $5.5B | $132.5M | ||
| Q1 24 | $5.6B | $130.7M |
| Q4 25 | $12.2B | $949.9M | ||
| Q3 25 | $12.1B | $868.8M | ||
| Q2 25 | $12.1B | $815.3M | ||
| Q1 25 | $11.9B | $789.8M | ||
| Q4 24 | $11.9B | $785.0M | ||
| Q3 24 | $12.3B | $786.6M | ||
| Q2 24 | $12.1B | $749.5M | ||
| Q1 24 | $12.2B | $721.8M |
| Q4 25 | 0.30× | 1.43× | ||
| Q3 25 | 0.30× | 1.70× | ||
| Q2 25 | 0.30× | 1.92× | ||
| Q1 25 | 0.30× | 2.02× | ||
| Q4 24 | 0.31× | 2.01× | ||
| Q3 24 | 0.30× | 2.18× | ||
| Q2 24 | 0.31× | 2.93× | ||
| Q1 24 | 0.30× | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $259.0M | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 2.18× | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $16.3M | ||
| Q3 25 | $55.0M | $35.7M | ||
| Q2 25 | $78.0M | $-26.5M | ||
| Q1 25 | $87.0M | $7.8M | ||
| Q4 24 | $47.0M | $-3.9M | ||
| Q3 24 | $17.0M | $-23.0M | ||
| Q2 24 | $58.0M | $22.7M | ||
| Q1 24 | $-74.0M | $-29.7M |
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $-28.9M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-23.3M | ||
| Q2 24 | — | $21.6M | ||
| Q1 24 | — | $-31.5M |
| Q4 25 | — | 8.6% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | -18.7% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | — | -16.5% | ||
| Q2 24 | — | 17.0% | ||
| Q1 24 | — | -28.5% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | 2.18× | 9.62× | ||
| Q3 25 | 0.52× | 2.06× | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 2.61× | -0.27× | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.74× | — | ||
| Q1 24 | -0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGO
| Insurance Segment | $226.0M | 82% |
| Other | $37.0M | 13% |
| Gain Loss On Investments Member1 | $8.0M | 3% |
| Non Credit Impairment Related Unrealized Fair Value Gains Losses On Credit Derivatives | $6.0M | 2% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
